Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stress Test For WHO’s Quality Certificate Scheme In The Americas

Executive Summary

A project being run in the Americas will assess the way that the Certificate of a Pharmaceutical Product is used and whether it meets the needs of countries in the region. The move is part of the revision of the World Health Organization’s quality certification scheme.

You may also be interested in...



New Manufacturing Technologies And Regulatory Convergence Expected To Improve Access In Developing Countries

The key to increasing access to biopharmaceuticals and vaccines in developing countries and to break affordability barriers is through advanced manufacturing platforms and regulatory partnerships such as AVAREF and through WHO's standards setting activities. Yet doubts about the continuing viability of the CPP in promoting access were expressed at recent industry meeting. 

WHO Consults On Revised Scheme To Certify Quality Of Pharmaceutical Products

The WHO has proposed a revised certification scheme on the quality of pharmaceutical products to address recent changes in the drug regulation environment, including the rapid globalization of the pharmaceutical manufacturing sector. 

Scottish HTA body OKs Lynparza For Earlier Use In Ovarian Cancer

AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.

Topics

UsernamePublicRestriction

Register

PS123929

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel